PSA Screening for Prostate Cancer: Evidence Summary

Introduction to Guideline Recommendations

The American College of Physicians emphasizes that physicians should not offer PSA screening unless prepared to engage in shared decision-making enabling informed choice with full understanding of benefits and harms 2
The BMJ provides a weak recommendation against PSA screening, acknowledging that most informed men would decline screening, though some may choose it after understanding the trade-offs 1

PSA screening provides at most a small reduction in prostate cancer-specific mortality, with approximately 1.3 deaths prevented per 1000 men screened over 13 years, and no reduction in all-cause mortality 1
The European Randomized Study of Screening for Prostate Cancer (ERSPC) found that 1,410 men need to be screened and 48 additional cancers detected to prevent 1 prostate cancer death 3
Overdiagnosis is a significant harm, with 29-44% of all PSA-detected cancers representing overdiagnosis 4
For every 1 prostate cancer death prevented, 37 additional men receive a cancer diagnosis through screening, experiencing no benefit but exposed to all treatment harms 1

For men aged 55-69 years, shared decision-making is essential before any screening occurs, and life expectancy must be at least 10 years for any potential benefit 3
Men aged 70+ years should not be screened, as harms clearly outweigh benefits, with greater risk of false-positives, biopsy complications, and treatment-related morbidity 4
No evidence supports screening men under 55 years, except those at very high risk, such as strong family history or African American race 3

The sensitivity of PSA for detecting aggressive cancer is 91% (PSA ≥4.0 μg/L), but many detected cancers are not clinically significant 7, 4
Common pitfalls that cause false elevations or reductions in PSA levels include benign prostatic hyperplasia, prostatitis, 5α-reductase inhibitors, and recent urinary catheterization 5, 8
Treatment complications are severe and common, affecting quality of life substantially, with urinary incontinence, erectile dysfunction, and bowel symptoms being common side effects 1, 5

For men aged 55-69 years asking about screening, use a structured discussion framework to explain the small potential benefit, describe the common harms, and assess patient values 1
Only proceed with screening if the patient expresses a clear preference for it after this discussion 1
Biennial screening reduces harms compared to annual screening while maintaining most benefits, and ERSPC used 2-4 year intervals 3